news
Could viral vector shortages disrupt the COVID-19 vaccine roll-out?
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
List view / Grid view
GlobalData
Filter the results
news
CRISPR therapies could be one of the most transformative in human history, says GlobalData
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
article
Diabetes and obesity: treatment and trials update
European Pharmaceutical Review reports on some of the latest developments in treatments for type 2 diabetes and obesity.
news
Launch of generic oncology medications to improve treatment access in India
GlobalData suggests the recent approval of new generics in oncology should enhance access and adherence to cancer treatment by reducing costs borne by patients.
article
COVID’s impact on cancer therapeutics: clinical trial and treatment disruptions
In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
news
Disinformation and safety concerns could prevent successful COVID-19 vaccination campaigns
Research suggests at least a fifth of the US population are resistant to receiving a COVID-19 vaccine, reports suggest this could be due to disinformation and safety concerns.
news
COVID-19 clinical trials have risen by 639 percent, says report
New findings have shown that there are currently over 4,000 clinical trials taking place investigating potential COVID-19 therapies.
news
AI to be most transformative technology for pharma, finds survey
A new report suggests artificial intelligence (AI) will be the most disruptive technology in the pharmaceutical industry this year and beyond.
news
Israel set to be first country to vaccinate entire population against COVID-19
A new report has said that Israel is expected to be the first country in the world to vaccinate its population against COVID-19.
news
Pfizer COVID-19 vaccine set to generate sales of $30 billion
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
news
Value of pharma’s M&A deals remain high, despite COVID-19
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
news
COVID-19 is benefiting contract manufacturing services, suggest reports
Reports have found that the COVID-19 pandemic is providing new opportunities for contract and development manufacturing organisations (CDMOs).
article
Clinical trial disruptions: is it all down to COVID-19?
This article explores how COVID-19 has impacted clinical investigation sites and what companies could do to mitigate the effect on trials moving forwards.
news
Lack of skill and talent biggest challenge to digital transformation in pharma
A report has found that the biggest hurdle for digital transformation in pharma is a lack of specific skills and talents, followed by organisational silos.
news
Differences in remdesivir efficacy due to trial variances, not drug, report says
After remdesivir showed little effect against COVID-19 in the SOLIDARITY trial, a new report has suggested this is due to the structure of the study.